Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Khurana, Sharad
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage	Recruiting	3	450	US	DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	12/22	12/22
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Recruiting	3	550	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	02/29
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML	Recruiting	1	50	US	Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®	Oryzon Genomics S.A.	Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	11/25	11/25
Johnson, Audrey
BBI-TP-3654-102, NCT04176198: A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis	Recruiting	1/2	240	Europe, Canada, Japan, US, RoW	Nusivertib, TP-3654, Ruxolitinib, Jakafi, Momelotinib, Ojjaara	Sumitomo Pharma America, Inc.	Myelofibrosis	04/27	04/30
NCT04282668: A Study of TAS1440 With ATRA in Subjects With r/r AML	Terminated	1	52	US	TAS1440, TAS1440 + ATRA, Tretinoin, Vesanoid	Taiho Oncology, Inc.	Acute Myeloid Leukemia	02/24	02/24